Provided by Tiger Trade Technology Pte. Ltd.

Callan JMB Inc.

2.49
+0.11004.62%
Post-market: 2.48-0.0100-0.40%19:45 EDT
Volume:337.97K
Turnover:825.05K
Market Cap:14.32M
PE:-1.29
High:2.55
Open:2.44
Low:2.30
Close:2.38
52wk High:5.61
52wk Low:0.6504
Shares:5.75M
Float Shares:2.43M
Volume Ratio:0.36
T/O Rate:13.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9288
EPS(LYR):-1.8200
ROE:-300.33%
ROA:-64.24%
PB:21.01
PE(LYR):-1.37

Loading ...

Callan Jmb Inc - May Offer up to $200 Mln in Securities - SEC Filing

THOMSON REUTERS
·
May 27

Callan JMB expands $175,000 per month infrastructure engagement

TIPRANKS
·
May 20

Callan JMB extends public sector infrastructure contract worth about $1.05 million over six months

Reuters
·
May 20

Callan JMB Expands Long-Standing Public Sector Infrastructure Engagement

GlobeNewswire
·
May 20

Callan Jmb Q1 EPS $(0.59) Down From $(0.32) YoY, Sales $1.106M Down From $1.449M YoY

Benzinga Earnings
·
May 16

Callan JMB Q1 FY26 net loss widens 159% to $3.22 million; revenue falls 24% to $1.11 million

Reuters
·
May 16

Callan JMB announces The Atlas Complex in Alabama

TIPRANKS
·
Apr 20

Callan JMB signs partnership agreement with India’s Walker’s Pharmaceuticals for Atlas Complex

Reuters
·
Apr 20

Callan Jmb Inc - Intends to Pursue Foreign-Trade Zone Subzone Designation for Atlas Complex

THOMSON REUTERS
·
Apr 20

Callan Jmb Inc - Atlas Complex Expected to Bring 250–300 Jobs and Long-Term Capital Investment to Marion

THOMSON REUTERS
·
Apr 20

Callan Jmb Inc - Announces Atlas Complex, 150 Acre Campus in Alabama for Pharmaceutical Onshoring

THOMSON REUTERS
·
Apr 20

Callan Jmb: Complaint Filed by Eddie Patent Holdings Does Not Impact Operations, Strategic Partnerships, or Ongoing Projects

THOMSON REUTERS
·
Apr 18

Callan JMB faces lawsuit filed by Eddie Patent Holdings in Texas federal court

Reuters
·
Apr 18

Callan JMB gets Nasdaq notice for falling below $2.5 million equity requirement

Reuters
·
Apr 11

Callan JMB Successfully Deploys Rapid Redistribution of Critical Pharmaceuticals to Combat Localized Disease Outbreaks for Longstanding Customer

GlobeNewswire
·
Apr 07

Callan JMB FY25 operating loss widens to $7.0 million; revenue falls to $5.7 million

Reuters
·
Apr 01

Callan JMB Reports Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Apr 01

Callan JMB to provide oversight for JKB-122 manufacturing scale-up

TIPRANKS
·
Mar 27

Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight

Reuters
·
Mar 27

Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement

GlobeNewswire
·
Mar 27